Welcome to the International Pompe Association (IPA)
The IPA Board wants to take this opportunity to share some news with you.
Effective September 1, 2014 Allan Muir has stepped down as Chair of the IPA and Tiffany House was selected by the Board to serve as the new Chair.
The IPA and the Pompe Community are extremely grateful and fortunate to have had Allan's leadership and guidance as IPA Chair since 2006, and we are happy to announce that he will continue to serve on the Board of the IPA.
Tiffany House is looking forward to continuing to serve and to work with you in her new position.
The IPA Board
The IPA is excited to announce that the first annual International Pompe Day on April 15 2014 was a resounding success!
Patient organizations, individuals, physicians, and industry partners from all over the world participated in recognizing and celebrating our community, and raising awareness of Pompe disease.
The ways in which International Pompe Day was celebrated were as diverse as our patient population, but the underlying theme and message was clear: Together We Are Strong!
The Acid Maltase Deficiency Association (AMDA), the United States Pompe patient organization, is compiling a Commemorative Book of the activities on the first annual International Pompe Day. This book will be available soon - information will be posted on the IPA (www.worldpompe.org) and AMDA (www.amda-pompe.org) websites regarding how to order your copy when it becomes available.
Wednesday June 18, 2014 Dr. Carine van Capelle received her PhD on 'Children with Pompe disease: clinical characteristics, peculiar features and effects of enzyme replacement therapy'.
Pompe disease presents as a continuous spectrum of clinical phenotypes in which progressive muscle weakness is the main manifestation. Patients with the classic-infantile form of this disease have virtually no residual enzyme activity and are at the severe end of the spectrum, while patients with a certain level of residual enzyme activity present milder phenotypes at the other end of the spectrum.
The first results of enzyme replacement therapy (ERT) with recombinant human alfa glucosidase were promissing since most patients with the classic-infantile form of Pompe disease survived far beyond the first year of life. But, there is still little known about the long-term treatment effects in this group of patients. Much less is known about the natural course of disease in children with less progressive phenotypes and how they respond to ERT. This thesis describes the clinical spectrum of children with Pompe disease, compares them with adult patients, and evaluates the effects of ERT in these childhood Pompe patients. Furthermore it describes the long-term outcome of ERT in patients with classic-infantile Pompe disease, for a maximum period of 14 years, and compares the functioning of these treated infants with that of children with less progressive forms of Pompe disease.